CN108714194A - A kind of natural composition prevented or treat hyperuricemia and gout - Google Patents
A kind of natural composition prevented or treat hyperuricemia and gout Download PDFInfo
- Publication number
- CN108714194A CN108714194A CN201810890997.0A CN201810890997A CN108714194A CN 108714194 A CN108714194 A CN 108714194A CN 201810890997 A CN201810890997 A CN 201810890997A CN 108714194 A CN108714194 A CN 108714194A
- Authority
- CN
- China
- Prior art keywords
- gout
- parts
- hyperuricemia
- dendrobium candidum
- natural composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 38
- 241000026010 Dendrobium candidum Species 0.000 claims abstract description 35
- 240000008042 Zea mays Species 0.000 claims abstract description 34
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 21
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 20
- 235000005822 corn Nutrition 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 18
- 241000219784 Sophora Species 0.000 claims abstract description 16
- 230000036541 health Effects 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 51
- 238000002360 preparation method Methods 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 241000202807 Glycyrrhiza Species 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 18
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 17
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 17
- 229940010454 licorice Drugs 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 15
- 235000007244 Zea mays Nutrition 0.000 claims description 13
- 229940089639 cornsilk Drugs 0.000 claims description 12
- 239000001231 zea mays silk Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 9
- 239000004744 fabric Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- -1 3 parts of Huai Goat Substances 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 22
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 20
- 229940116269 uric acid Drugs 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 102000003777 Interleukin-1 beta Human genes 0.000 description 11
- 108090000193 Interleukin-1 beta Proteins 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010018634 Gouty Arthritis Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 7
- 108010093894 Xanthine oxidase Proteins 0.000 description 7
- 102100033220 Xanthine oxidase Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 230000003631 expected effect Effects 0.000 description 6
- 229950000193 oteracil Drugs 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000010444 Acidosis Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 244000046101 Sophora japonica Species 0.000 description 3
- 235000010586 Sophora japonica Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000006101 laboratory sample Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241001076416 Dendrobium tosaense Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000320 anti-stroke effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008060 renal absorption Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
- 229940032415 zurampic Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of prevention or the natural compositions for the treatment of hyperuricemia and gout, belong to functional food or field of health care products.Its raw material contains the component of following weight proportion：3-5 parts of dendrobium candidum, 2-4 parts of the sophora bud, 1-3 parts of corn stigma, 1-2 parts of Radix Glycyrrhizae.The present composition can effectively prevent or treat hyperuricemia and gout, have effects that uric acid level and functions of detumescence, relieving inflammation in well-tuned body, and new product is provided for clinical prevention or treatment hyperuricemia and gout.
Description
Technical field
The present invention relates to it is a kind of prevention or treatment hyperuricemia and gout natural composition, belong to functional food or
Field of health care products.
Background technology
Hyperuricemia be by purine metabolic disturbance and (or) a kind of metabolic disease caused by underexcretion, height urine
Acidaemia causes urate crystal to be precipitated and be deposited on periarticular and causes inflammation, as gout, is mainly shown as and sends out repeatedly
Acute and chronic urarthritis, tophus, calculus urate, uric acid nephropathy for making etc..Gout morbidity has apparent heterogeneity,
And not all hyperuricemia develops into gout, about 10% Patients with Hyperuricemia finally will appear gout clinical condition
Shape.
With the variation of social crowd structure and dietary structure, the illness rate of hyperuricemia and gout becomes in rising year by year
Gesture not only brings obstacle to patient's daily routines, and need to spend high medical expense, becomes urgently to be resolved hurrily public strong
Kang Wenti.According to reporting in recent years, there are about hyperuricemia persons 1.2 hundred million in China at present, account for about the 10% of total population, data are shown
The Patients with Hyperuricemia of 10%-15% will appear gout symptom, it is contemplated that the year two thousand twenty China will have 100,000,000 patient with gout.High lithemia
Positive correlation is presented in mass formed by blood stasis and the diseases such as gout and diabetes, hyperlipidemia, hypertension, coronary heart disease, metabolic syndrome, becomes only
This is in the second largest metabolic disease of diabetes.
For the treatment of hyperuricemia, it is the effective means prevented gout and occurred to reduce serum Uric Acid Concentration by drug.
This kind of drug includes that medicine for improving uric acid excretion (Benzbromarone, propane sulfonic acid etc.) and xanthine oxidase (XOD) inhibitor be not (fast
Purine alcohol, Febustat etc.), this kind of drug generally has larger side effect.In addition, the gout of in December, 2015 FDA approvals is controlled
Transport proteins of the new drug Zurampic by inhibition renal reabsorption uric acid is treated, increases uric acid excretion to reduce blood uric acid, though
So it can control the content of serum uric acid with xanthine oxidase inhibitor combination well, but it equally exists kidney and painstaking effort
Security risk in terms of pipe.On the other hand, for the acute attack of gout, it is contemplated that the year two thousand twenty China will have 100,000,000 patient with gout, face
Common such as colchicin, non-steroidal anti-inflammatory drugs and glucocorticoid can be used for alleviating acute gouty arthritis on bed, but
Such drug dose is larger, and side effect is more, and many patients are not resistant to；Emerging il-1 (IL-1) receptor blocking pharmacon profit
Monoclonal antibody (Canakinumab) etc. is received in Nahsi general (Rilonacept), anti-Interleukin -1β (IL-1 β) monoclonal antibody card, although energy
The joint symptoms of invalid to conventional antiinflammatory pain management or intolerable patient with gout are relieved, but its R&D costs is high
It is expensive, administering mode limitation, and there are serious safety issues.
If a kind of wholefood can be searched out, and have anti-trioxypurine and anti-inflammatory effect, it can be to greatest extent
Reduce the generation of toxic side effect.
Invention content
Based on the above present situation, the present invention is quasi- to provide a kind of natural products combination preventing or treat hyperuricemia and gout
Object and application thereof.
The present invention provides a kind of prevention or the food or Halth-care composition for the treatment of hyperuricemia and gout, raw materials
Component containing following weight proportion：3-5 parts of dendrobium candidum, 2-4 parts of the sophora bud, 1-3 parts of corn stigma, 1-2 parts of Radix Glycyrrhizae.
Further, raw material preferably comprises the component of following weight proportion：4 parts of dendrobium candidum, 3 parts of the sophora bud, corn stigma
2 parts, 1 part of Radix Glycyrrhizae.
The present invention provides it is a kind of prevention or treatment hyperuricemia and gout food or Halth-care composition, preferably its
Raw material contains the component of following weight proportion：3-5 parts of dendrobium candidum ultrafine powder, 2-4 parts of Huai Goat, Corn silk P.E
1-3 parts, 1-2 parts of licorice.
Further, raw material preferably comprises the component of following weight proportion：4 parts of dendrobium candidum ultrafine powder, sophora bud extraction
3 parts of object, 2 parts of Corn silk P.E, 1 part of licorice.
The Yunnan dendrobium candidum (Dendrobium officinale Kimura et Migo) used in the present invention is orchid
Section herbaceous plant is born in height above sea level up on the dark and damp rock in 1600 meters of mountainous region half.Its stem is used as medicine, sweet in flavor, cold nature, beneficial stomach life
Tianjin, nourishing Yin and clearing heat, for pyreticosis Tianjin wound, dry polydipsia, deficiency of stomach-Yin, deficiency of food retch, after being ill abnormal heat do not move back, fire excess from yin deficiency, bone
Steam the dark unknown, muscles and bones impotence of labor heat, mesh.Dendrobium candidum has the function of promoting the production of body fluid, hypoglycemic and increase immunity of organisms.
The preparation method of dendrobium candidum ultrafine powder carries out as steps described below：The dendrobium candidum of fresh harvesting removes blade,
It cleans, drain；The dendrobium candidum to drain away the water is placed in constant temperature 4h in freeze drying equipment；By dried iron sheet stone under low temperature
Dry measure used in former times carries out ultramicro grinding with micronizer；Co 60 radiation sterilization is carried out, dendrobium candidum ultrafine powder is obtained.
The sophora bud used in the present invention is the dry flower and flower of legume Chinese scholartree (Sophora japonica L.).Chinese scholartree
Cold, the sweet taste of rice, for cooling blood and hemostasis, reduces blood pressure, pre- anti-stroke.It is clinically used for treatment psoriasis, the tuberculosis of cervical lymph nodes
With heat furuncle.
The preparation method of Huai Goat carries out as steps described below：The sophora bud is weighed, is 1 according to solid-liquid ratio:10 (g/
Ml water) is added, with Rotary Evaporators boiling waterbath 1h, the liquid filter-cloth filtering after extraction takes filtrate and taken out with filter paper vacuum
Filter, vacuum freeze drying obtain freeze-dried powder, as Huai Goat.
The corn stigma used in the present invention is the style and column cap of grass maize (Zea mays L.).Corn
Must be sweet in flavor, light, it is mild-natured, there is the effect of inducing diuresis to remove edema, clearing liver cholagogic.It is clinically used for treating main oedema, dribbling urination, jaundice, courage
Capsulitis, gall stone, hypertension, diabetes, alactation.
The preparation method of Corn silk P.E carries out as steps described below：Dry corn stigma is weighed, is 1 according to solid-liquid ratio:
Water is added in 10 (g/ml), and with Rotary Evaporators boiling waterbath 1h, the liquid filter-cloth filtering after extraction takes filtrate and true with filter paper
Sky filters, vacuum freeze drying, obtains freeze-dried powder, as Corn silk P.E.
The Radix Glycyrrhizae used in the present invention is pulse family, Glycyrrhiza perennial herb, and root is sturdy with root-like stock, is in a kind of help
Herbal medicine.With anti-inflammatory, anti-allergic effects.
The preparation method of licorice carries out as steps described below：Radix Glycyrrhizae is weighed, is 1 according to solid-liquid ratio:10 (g/
Ml water) is added, with Rotary Evaporators boiling waterbath 1h, the liquid filter-cloth filtering after extraction takes filtrate and taken out with filter paper vacuum
Filter, vacuum freeze drying obtain freeze-dried powder, as licorice.
The present composition can be prepared into food or health products by way of conventional, such as directly play powder preparation, or
It is prepared into lozenge, beverage, or is prepared into corresponding final product form after extracting.If each component of the present invention is beaten powder preparation group
Object is closed, conventional grain size, including but not limited to 100~200 mesh can be selected, can also selecting Ultramicro-powder, (grain size is less than 300
Mesh).
The present composition can be absorbed by gastrointestinal tract, can be administered orally.The present invention also provides above-mentioned compositions
Or its extract is preparing the purposes in preventing or treating the food or health products of hyperuricemia and gout.It is of the present invention to carry
Object is taken, including is not limited to water extract, alcohol extract and each active component, such as polyphenol, polysaccharide, flavones etc..Further, institute
It is the food or health products for preventing or treating hyperuricemia and gout to state food or health products.
Gout of the present invention includes at least acute gouty arthritis, tophus is formed, gouty arthritis,chronic
Deng.Further, the food or health products are anti-inflammatory food or health products.Further, the food or health products are
Reduce the food or health products of serum uric acid level.Wherein, the food or health products are to reduce the food of IL-1 β or guarantor in blood
Strong product.
The present invention using the present composition the study found that can effectively be prevented or be treated caused by Oxonic Acid sylvite (PO)
Hyperuricemia and MSU caused by gout, there is good adjustings uric acid and anti-inflammatory efficacy, be clinical prevention or treatment is high urinates
Acidaemia and gout provide new product.
The raw material that the present composition uses is natural plants, and edible, compares known hyperuricemia
With gout drug, also with the low advantage of toxic side effect, patient compliance is more preferable.
Based on above-mentioned discovery, the present invention also provides the products containing the present composition to prepare prevention or the high urine for the treatment of
Purposes in the food and health products of acidaemia and gout.
Active constituent in above-mentioned " product " includes at least the present composition, and this is a kind of, it is of course also possible to only with
The present composition is active constituent.In addition, can also include relevant auxiliary material or complementary ingredient in the product.
The product is given by gastrointestinal tract absorption features, and different preparation types can be prepared according to actual demand,
Such as liquid form, solid form.Different preparation types is given, different auxiliary materials can be selected.
The present composition can effectively prevent or treat hyperuricemia and gout, have uric acid water in well-tuned body
The effect of gentle functions of detumescence, relieving inflammation, provides new product for clinical prevention or treatment hyperuricemia and gout.
Description of the drawings
Fig. 1 is influence of the composition to hyperuricemia model mice serum uric acid.
The influence that Fig. 2 is composition to hyperuricemia model mouse uric acid excretion amount for 24 hours.
Fig. 3 is composition on the active influences of hyperuricemia model mouse liver XOD.
Fig. 4 is the influence that composition expresses hyperuricemia model mouse kidney URAT1.
Fig. 5 is influence of the composition to acute gouty arthritis rat blood serum IL-1 β levels.
Fig. 6 is influence of the composition to acute gouty arthritis synovial cells in rats IL-1 β levels.
Specific implementation mode
With reference to specific embodiment, the present invention is further elaborated, but the invention is not limited in following embodiment,
The raw material can obtain unless otherwise specified from open commercial sources.
One, embodiment is prepared
Embodiment 1
1. sample preparation
The preparation method of dendrobium candidum ultrafine powder carries out in accordance with the following steps：The dendrobium candidum of fresh harvesting removes blade,
It cleans, drain；The dendrobium candidum to drain away the water is placed in constant temperature 4h in freeze drying equipment；By dried iron sheet stone under low temperature
Dry measure used in former times carries out ultramicro grinding with micronizer；Co 60 radiation sterilization is carried out, dendrobium candidum ultrafine powder is obtained.
The preparation method of sophora bud Ultramicro-powder, corn stigma Ultramicro-powder, Radix Glycyrrhizae Ultramicro-powder carries out in accordance with the following steps：After drying
The sophora bud, corn stigma, Radix Glycyrrhizae carry out ultramicro grinding with micronizer；Co 60 radiation sterilization is carried out, sophora bud Ultramicro-powder, jade are obtained
Rice must Ultramicro-powder and Radix Glycyrrhizae Ultramicro-powder.
In the ratio of 3 parts of dendrobium candidum ultrafine powder, 2 parts of sophora bud Ultramicro-powder, 1 part of corn stigma Ultramicro-powder, 1 part of Radix Glycyrrhizae Ultramicro-powder
Mixing for standby use.
Embodiment 2
1. sample preparation
The same embodiment of preparation method of dendrobium candidum ultrafine powder, sophora bud Ultramicro-powder, corn stigma Ultramicro-powder, Radix Glycyrrhizae Ultramicro-powder
1.It is standby in the ratio mixing of 5 parts of dendrobium candidum ultrafine powder, 4 parts of sophora bud Ultramicro-powder, 3 parts of corn stigma Ultramicro-powder, 2 parts of Radix Glycyrrhizae Ultramicro-powder
With.
Embodiment 3
1. sample preparation
The preparation method of dendrobium candidum ultrafine powder is the same as embodiment 1.
The preparation method of Huai Goat carries out as steps described below：The 100g sophora bud is weighed, 1000ml water is added, with rotation
Turn evaporimeter boiling waterbath 1h, the liquid filter-cloth filtering after extraction takes filtrate and is filtered by vacuum with filter paper, and vacuum refrigeration is dry
It is dry, obtain freeze-dried powder, as Huai Goat.
The preparation method of Corn silk P.E is as follows：100g drying corn stigmas are weighed, 1000ml water is added, uses rotary evaporation
Instrument boiling waterbath 1h, the liquid filter-cloth filtering after extraction take filtrate and are filtered by vacuum with filter paper, vacuum freeze drying, obtain
Freeze-dried powder, as Corn silk P.E.
The preparation method of licorice is as follows：100g Radix Glycyrrhizaes are weighed, 1000ml water are added, with Rotary Evaporators boiling water bath
1h is extracted, the liquid filter-cloth filtering after extraction takes filtrate and is filtered by vacuum with filter paper, vacuum freeze drying, obtains freeze-dried powder, i.e.,
For licorice.
It is milled after the drying of said extracted object, by 3 parts of dendrobium candidum ultrafine powder, 2 parts of Huai Goat, Corn silk P.E 1
Part, the ratio mixing for standby use of 1 part of licorice.
Embodiment 4
1. sample preparation
Dendrobium candidum ultrafine powder, Huai Goat, corn extract, licorice preparation method with embodiment 3.
It is standby in the ratio mixing of 5 parts of dendrobium candidum ultrafine powder, 4 parts of Huai Goat, 3 parts of Corn silk P.E, 2 parts of licorice
With.
Embodiment 5
1. sample preparation
Dendrobium candidum ultrafine powder, Huai Goat, corn extract, licorice preparation method with embodiment 3.
It is standby in the ratio mixing of 4 parts of dendrobium candidum ultrafine powder, 3 parts of Huai Goat, 2 parts of Corn silk P.E, 1 part of licorice
With.
Two, animal experiment
2. experimental animal
Mouse：Kunming kind, SPF grades of 20-25g, male, rat：SD kinds, SPF and 200-250g, male sell unit：South
The Jiangning Districts Jing Shi Qinglongshan animal reproduction field, quality testing unit：Unit is sold in Jiangning county Qinglongshan animal reproduction field
Credit number：SCXK (Soviet Union) 2017-0001, experimental unit's licensing number：SYXK (Soviet Union) 2016-0011
3. Studies on Animal Models of Hyperuricemic Mice pharmacological research experimental method
Animal packet：Adaptability is raised one week after grouping, is divided into 6 groups, every group 10, respectively：Blank group, model
The low middle high dose group of group, positive drug group, laboratory sample is 3 groups, amounts to 6 groups
Sample：Mixed dendrobium candidum ultrafine powder, Huai Goat, corn extract, licorice (are implemented real
Example 5) solution of 0.05g/ml, 1g/ml, 2g/ml, and ultrasound 10min are formulated as with distilled water, 1h is pressed after daily modeling
10ml/kg gavages give the Ultramicro-powder solution of mouse various concentration, continue 7, and low middle high dose group is respectively 0.5g/kg, 1g/
kg、2g/kg
Hyperuricemia derivant Oxonic Acid sylvite：The suspension of 25mg/ml, and ultrasound are formulated as with 0.5%CMC sodium
10min, gavage modeling continue 7, dosage 10ml/kg
Positive drug：Allopurinol is configured to 1mg/ml by distilled water, and by 10mg/kg, 1h is administered after daily modeling, makes
With preceding ultrasound 10min
Uric acid excretion measures fixed for 24 hours：After administration 1h on the 5th, mouse is placed in metabolic cage, after adapting to 1, in administration
Collect urine for 24 hours within 6th.Room temperature centrifuges 10min under 2000 × g centrifugal conditions, takes supernatant, after measuring volume of urine, sets
It is saved backup in 4 DEG C
After administration on the 7th after 1h, eyeball of mouse rear vein beard takes blood, centrifuges 5min under 10000 × g centrifugal conditions, takes
Serum is placed in 4 DEG C and saves backup.Then the neck that breaks puts to death animal, quickly divides on ice platform and takes liver organization and renal tissue, through liquid
- 70 DEG C of chilled nitrogen postposition saves backup
Urine and serum：Uric acid level is detected by kit (Nanjing is built up) method
Liver：Uric acid level and XOD activity in liver homogenate are detected by kit (Nanjing is built up) method
Kidney：Western Blot methods detect the expression of kidney uric acid reabsorption transport protein URAT1
4. rat acute urarthritis model pharmacology research experiment method
Animal packet：Adaptability is raised one week after grouping, is divided into 6 groups, every group 10, respectively：Blank group, model pair
According to group, positive drug group, the low middle high dose group of laboratory sample is 3 groups, amounts to 6 groups
Sample：By mixed dendrobium candidum ultrafine powder, Huai Goat, corn extract, licorice (embodiment
5) solution of 0.05g/ml, 1g/ml, 2g/ml, and ultrasound 10min are formulated as with distilled water, 1h presses 10ml/ after daily modeling
Kg gavages give the Ultramicro-powder solution of rat various concentration, continue 5, and low middle high dose group is respectively 0.35g/kg, 0.7g/
kg、1.4g/kg
Acute gouty arthritis derivant MSU：It is 40mg/ml with 0.9% normal saline, and ultrasound 10min,
1h after being administered in last day injects 100 μ l to rat ankle joint chamber
Positive drug：Indomethacin is formulated as 1mg/ml with 0.9% physiological saline, by 5mg/kg gastric infusions, continues 5
Day, use preceding ultrasound 10min
Joint week diameter measure：Using thread method detect rat articular Zhou Jing, minute point select 0h, 2h, 4h, 8h,
12h、24h
Rat eye rear vein beard takes blood after for 24 hours, centrifuges 5min under 10000 × g centrifugal conditions, takes serum, is placed in 4 DEG C
It saves backup.Then the neck that breaks puts to death animal, the quick Fen Qu synovial tissue of joint on ice platform, through -70 DEG C of guarantors of liquid nitrogen frozen postposition
It deposits spare
Serum：It is horizontal by enzyme linked immunosorbent assay (ELISA) (ELISA) kit (Shenzhen Xin Bosheng) method detection IL-1 β
Synovial membrane：It is horizontal by ELISA kit (Shenzhen Xin Bosheng) method detection IL-1 β
5. experimental result
Data are the mean+SDs of 10 mice serum uric acid levels in Fig. 1, are carried out with one-way anova
(### represents the P < 0.001 compared with normal group, and * represents the P < 0.05 compared with model control group, and * * are represented and mould for variance analysis
Type control group compares P < 0.01, and * * * represent the P < 0.001 compared with model control group).As seen from the figure：Oxonic Acid sylvite causes
Mice serum uric acid significantly increases, and prompts modeling success；Various dose test composition can be different degrees of alleviation serum urine
The raising of acid, significant difference is more embodied with model control group；Positive control drug has also embodied expected anti-trioxypurine
Effect shows that experimental result is genuine and believable.
Data are the mean+SDs of 10 mice serum uric acid levels in Fig. 2, are carried out with one-way anova
(### represents the P < 0.001 compared with normal group, and * represents the P < 0.05 compared with model control group, and * * are represented and mould for variance analysis
Type control group compares P < 0.01, and * * * represent the P < 0.001 compared with model control group).As seen from the figure：Oxonic Acid sylvite causes
Uric acid excretion amount significantly reduces mouse for 24 hours, prompts modeling success；Various dose test composition can be different degrees of recovery urine
Acid excretion, significant difference is more embodied with model control group；Positive control drug has also embodied expected effect, shows
Experimental result is genuine and believable.
Data are 10 active mean+SDs of mouse liver XOD in Fig. 3, with the sides of progress one-way anova
(### represents the P < 0.001 compared with normal group, and * represents the P < 0.05 compared with model control group, and * * are represented and model for difference analysis
Control group compares P < 0.01, and * * * represent the P < 0.001 compared with model control group).As seen from the figure：Oxonic Acid sylvite causes small
Mouse liver XOD activity significantly increases, and prompts modeling success；Various dose test composition can be different degrees of inhibition liver
XOD activity, significant difference is more embodied with model control group；Positive control drug has also embodied expected effect, table
Bright experimental result is genuine and believable.
Data are the mean+SDs of 4 mouse kidney URAT1 albumen relative expressions in Fig. 4, use one-way
Anova carries out variance analysis, and (### represents the P < 0.001 compared with normal group, and * represents the P < compared with model control group
0.05, * * * represent the P < 0.001 compared with model control group).As seen from the figure：Oxonic Acid sylvite causes mouse kidney URAT1 tables
It is increased up to notable, prompts modeling success；Various dose test composition can be different degrees of downward kidney URAT1 albumen tables
It reaches, significant difference is more embodied with model control group；Positive control drug has also embodied expected effect, shows to test
Real result is credible.
Table 1：Influence (cm) of the composition to acute gouty arthritis rat articular Zhou Jing
Data are the mean+SDs of 10 rat different time points joint Zhou Jing in table 1, with one-way anova
Carrying out variance analysis, (## represents the P < 0.01 compared with normal group, and ### represents the P < 0.001 compared with normal group, and * is represented and mould
Type control group compares P < 0.05, and * * represent the P < 0.01 compared with model control group, and * * * represent the P < compared with model control group
0.001).As seen from the figure：MSU causes rat articular swelling, in 4h, 8h, 12h, shows significant difference for 24 hours, prompts modeling
Success；Various dose test composition can be different degrees of alleviation MSU caused by rat articular week diameter increase, with model comparison
Group more embodies significant difference；Positive control drug has also embodied expected effect, shows that experimental result is genuine and believable.
Data are the mean+SDs of 10 rat blood serum IL-1 β levels in Fig. 5, are carried out with one-way anova
Variance analysis (### represents the P < 0.001 with normal group compared with, and * represents the P < 0.05 with model control group compared with, * * * representative and
Model control group compares P < 0.001).As seen from the figure：MSU causes rat blood serum IL-1 β are horizontal significantly to increase, prompt modeling at
Work(；Various dose test composition can be different degrees of downward serum IL -1 β it is horizontal, with more middle and high dose of model control group
Amount embodies significant difference；Positive control drug has also embodied expected effect, shows that experimental result is genuine and believable.
Data are the mean+SDs of 10 synovial cells in rats IL-1 β levels in Fig. 6, with one-way anova
Carrying out variance analysis, (### represents the P < 0.001 compared with normal group, and * represents the P < 0.05 compared with model control group, and * * are represented
The P < 0.01 compared with model control group, * * * represent the P < 0.001 compared with model control group).As seen from the figure：MSU causes rat
Synovial tissue IL-1 β are horizontal significantly to be increased, and modeling success is prompted；Various dose test composition can be different degrees of downward slide
Membrane tissue IL-1 β are horizontal, and significant difference is more embodied with model control group；Positive control drug has also embodied expected
Effect shows that experimental result is genuine and believable.
It the above is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred embodiment is not construed as pair
The limitation of the present invention, protection scope of the present invention should be subject to claim limited range.For the art
For those of ordinary skill, without departing from the spirit and scope of the present invention, several improvements and modifications can also be made, these change
Protection scope of the present invention is also should be regarded as into retouching.
Claims (10)
1. the natural composition of a kind of prevention or treatment hyperuricemia and gout, it is characterised in that：Its raw material contains following weight
Measure the component of proportioning：
3-5 parts of dendrobium candidum, 2-4 parts of the sophora bud, 1-3 parts of corn stigma, 1-2 parts of Radix Glycyrrhizae.
2. the natural composition of a kind of prevention according to claim 1 or treatment hyperuricemia and gout, feature exists
In：Its raw material contains the component of following weight proportion：
4 parts of dendrobium candidum, 3 parts of the sophora bud, 2 parts of corn stigma, 1 part of Radix Glycyrrhizae.
3. the natural composition of a kind of prevention according to claim 1 or 2 or treatment hyperuricemia and gout, feature
It is：Its raw material contains the component of following weight proportion：3-5 parts of dendrobium candidum ultrafine powder, 2-4 parts of Huai Goat, corn stigma
1-3 parts of extract, 1-2 parts of licorice.
4. the natural composition of a kind of prevention according to claim 3 or treatment hyperuricemia and gout, feature exists
In：Its raw material contains the component of following weight proportion：4 parts of dendrobium candidum ultrafine powder, 3 parts of Huai Goat, Corn silk P.E 2
Part, 1 part of licorice.
5. the natural composition of a kind of prevention according to claim 3 or 4 or treatment hyperuricemia and gout, feature
It is：The preparation method of dendrobium candidum ultrafine powder carries out as steps described below：The dendrobium candidum of fresh harvesting removes blade, washes
Only it, drains；The dendrobium candidum to drain away the water is placed in constant temperature 4h in freeze drying equipment；By dried dendrobium candidum under low temperature
Ultramicro grinding is carried out with micronizer；Co 60 radiation sterilization is carried out, dendrobium candidum ultrafine powder is obtained.
6. the natural composition of a kind of prevention according to claim 3 or 4 or treatment hyperuricemia and gout, feature
It is：The preparation method of Huai Goat carries out as steps described below：The sophora bud is weighed, is 1 according to solid-liquid ratio:10 (g/ml) add
Enter water, with Rotary Evaporators boiling waterbath 1h, the liquid filter-cloth filtering after extraction takes filtrate and is filtered by vacuum with filter paper, very
Vacuum freecing-dry obtains freeze-dried powder, as Huai Goat.
7. the natural composition of a kind of prevention according to claim 3 or 4 or treatment hyperuricemia and gout, feature
It is：The preparation method of Corn silk P.E carries out as steps described below：Dry corn stigma is weighed, is 1 according to solid-liquid ratio:10
(g/ml) water is added, with Rotary Evaporators boiling waterbath 1h, the liquid filter-cloth filtering after extraction takes filtrate and with filter paper vacuum
It filters, vacuum freeze drying, obtains freeze-dried powder, as Corn silk P.E.
8. the natural composition of a kind of prevention according to claim 3 or 4 or treatment hyperuricemia and gout, feature
It is：The preparation method of licorice carries out as steps described below：Radix Glycyrrhizae is weighed, is 1 according to solid-liquid ratio:10 (g/ml) add
Enter water, with Rotary Evaporators boiling waterbath 1h, the liquid filter-cloth filtering after extraction takes filtrate and is filtered by vacuum with filter paper, very
Vacuum freecing-dry obtains freeze-dried powder, as licorice.
9. the use of a kind of prevention or the natural composition for treating hyperuricemia and gout according to claim 1-8
On the way, the food or health products for preventing or treating hyperuricemia and gout are used to prepare into.
10. the preparation side of the natural composition of a kind of prevention according to claim 9 or treatment hyperuricemia and gout
Method, it is characterised in that：Powder preparation is directly played, or is prepared into lozenge, beverage, or is prepared into corresponding finished product shape after extracting
Formula.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810890997.0A CN108714194A (en) | 2018-08-07 | 2018-08-07 | A kind of natural composition prevented or treat hyperuricemia and gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810890997.0A CN108714194A (en) | 2018-08-07 | 2018-08-07 | A kind of natural composition prevented or treat hyperuricemia and gout |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108714194A true CN108714194A (en) | 2018-10-30 |
Family
ID=63913856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810890997.0A Pending CN108714194A (en) | 2018-08-07 | 2018-08-07 | A kind of natural composition prevented or treat hyperuricemia and gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108714194A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112022966A (en) * | 2020-10-10 | 2020-12-04 | 中国药科大学 | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
| CN113384612A (en) * | 2021-07-22 | 2021-09-14 | 江苏大学 | Anti-gout composition and preparation method and application thereof |
| CN113940970A (en) * | 2021-11-03 | 2022-01-18 | 吉林农业大学 | A composition with effects of resisting hyperuricemia and gouty arthritis |
| CN115518132A (en) * | 2022-10-24 | 2022-12-27 | 北京擎天数康科技有限公司 | Chinese medicinal compound composition for preventing and treating hyperuricemia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181345A (en) * | 2007-11-15 | 2008-05-21 | 南京大学 | Application of flos Sophora chromocor extract in the preparation of medicament for restrainting uric acid transporter URAT1 |
| CN104383292A (en) * | 2014-10-31 | 2015-03-04 | 南京葆赫生物技术有限公司 | Application of dendrobium officinale extract in preparation of medicine for preventing and/or treating hyperuricemia |
| CN104840816A (en) * | 2015-05-18 | 2015-08-19 | 云南润紫源生物科技股份有限公司 | Composite superfine powder for preventing and treating gout and hyperuricemia and preparation method thereof |
-
2018
- 2018-08-07 CN CN201810890997.0A patent/CN108714194A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181345A (en) * | 2007-11-15 | 2008-05-21 | 南京大学 | Application of flos Sophora chromocor extract in the preparation of medicament for restrainting uric acid transporter URAT1 |
| CN104383292A (en) * | 2014-10-31 | 2015-03-04 | 南京葆赫生物技术有限公司 | Application of dendrobium officinale extract in preparation of medicine for preventing and/or treating hyperuricemia |
| CN104840816A (en) * | 2015-05-18 | 2015-08-19 | 云南润紫源生物科技股份有限公司 | Composite superfine powder for preventing and treating gout and hyperuricemia and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 郭兵兵等: "微波法提取玉米须抗痛风活性组分的工艺研究", 《食品工业科技》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112022966A (en) * | 2020-10-10 | 2020-12-04 | 中国药科大学 | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
| CN112022966B (en) * | 2020-10-10 | 2022-03-08 | 中国药科大学 | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
| CN113384612A (en) * | 2021-07-22 | 2021-09-14 | 江苏大学 | Anti-gout composition and preparation method and application thereof |
| CN113940970A (en) * | 2021-11-03 | 2022-01-18 | 吉林农业大学 | A composition with effects of resisting hyperuricemia and gouty arthritis |
| CN115518132A (en) * | 2022-10-24 | 2022-12-27 | 北京擎天数康科技有限公司 | Chinese medicinal compound composition for preventing and treating hyperuricemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108714194A (en) | A kind of natural composition prevented or treat hyperuricemia and gout | |
| CN104352991A (en) | Traditional Chinese medicine preparation for treating gout and preparation method thereof | |
| CN103933224B (en) | A kind of Chinese medicine composition for treating gout | |
| CN104706759A (en) | Health product or pharmaceutical composition capable of promoting bone or joint health, and preparation method and application thereof | |
| KR20040030370A (en) | A functional food Containing herbes composition for allergy disease treatment | |
| CN103877438A (en) | Traditional Chinese medicine preparation for treating gout and production method thereof | |
| CN103893620B (en) | Chinese medicinal composition for preventing and treating diabetes and preparation method thereof | |
| CN100333758C (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN104922548A (en) | Chinese herbal preparation for treatment of ascariasis | |
| CN101850063A (en) | Medicinal preparation for preventing and treating gout and preparation method | |
| CN109820943A (en) | A kind of strong medicine preparation and preparation method thereof for treating gout | |
| CN106266109B (en) | It is a kind of to treat Chinese medicine composition of calculi in urinary system and preparation method thereof | |
| CN108815339A (en) | The Chinese medicine composition and preparation for treating urarthritis and/or hyperuricemia | |
| CN103705772B (en) | Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof | |
| CN104147540A (en) | Traditional Chinese medicine composition for treating malignant tumor | |
| CN104189267A (en) | Traditional Chinese medicine composition for treating kidney stone and preparation method of traditional Chinese medicine composition | |
| CN103908603B (en) | A kind of Chinese medicine composition treating gout and preparation method thereof | |
| CN100457143C (en) | Medication for treating gout | |
| CN103933154B (en) | A kind of Chinese medicine composition treating goat and preparation method thereof | |
| CN104873781A (en) | Traditional Chinese medicine for treating phlegm and heat-accumulated lung type chronic bronchitis and preparation method thereof | |
| CN109999076A (en) | It is a kind of adjust reverse cholesterol transport Chinese medicine composition and its application | |
| CN103751583A (en) | Traditional Chinese medicine composition for being diuretic and protecting liver and preparation method of composition | |
| CN104274720A (en) | Traditional Chinese medicine composition for removing urinary calculus and treating stranguria | |
| CN109908202A (en) | A kind of pharmaceutical composition and preparation method thereof for treating hyperuricemia | |
| CN103432418B (en) | Chinese medicine composition of a kind of gout pain relieving and its production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181030 |
|
| RJ01 | Rejection of invention patent application after publication |